휴온스글로벌
Financials
Valuation Metrics
휴온스글로벌's Market Cap is ₩3140B. At end of 2025 it was ₩6482B. Ranked #608 of 2,436 in KR market (top 25%), #239 of 1,649 on KOSDAQ (top 14%), #66 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 313.96B KRW | KR#608/2,436 Sec#66/234 |
| Revenue | 845.30B KRW | KR#438/2,436 Sec#17/234 |
| Net Income | 71.30B KRW | KR#287/2,436 Sec#20/234 |
| Total Assets | 1.56T KRW | KR#350/2,436 Sec#16/234 |
| Net Assets | 1.10T KRW | KR#267/2,436 Sec#14/234 |
| Employees | 121 | KR#1,487/2,436 Sec#118/234 |
| Value | ||
| P/E | 4.40x | KR#219/2,436 Sec#8/234 |
| P/B | 0.29x | KR#280/2,436 Sec#9/234 |
| P/S | 0.37x | KR#708/2,436 Sec#17/234 |
| EV/EBITDA | 5.47x | KR#249/2,436 Sec#4/234 |
| FCF Yield | 15.41% | KR#428/2,436 Sec#9/234 |
| Profitability | ||
| ROE | 6.51% | KR#846/2,436 Sec#65/234 |
| ROA | 4.56% | KR#705/2,436 Sec#56/234 |
| Op. Margin | 8.77% | KR#569/2,436 Sec#52/234 |
| Revenue Growth | -1.08% | KR#1,511/2,436 Sec#145/234 |
| Earnings Growth | -40.30% | KR#1,155/2,436 Sec#75/234 |
| Financial Health | ||
| Debt Ratio | 142.53% | KR#1,083/2,436 Sec#124/234 |
| Total Debt | 289.56B KRW | KR#403/2,436 Sec#21/234 |
| FCF | 48.38B KRW | KR#306/2,436 Sec#17/234 |
| Cash | 197.90B KRW | KR#272/2,436 Sec#11/234 |
| Current Ratio | 1.80x | KR#1,085/2,436 Sec#119/234 |
| Net Debt/EBITDA | 1.24x | KR#826/2,436 Sec#58/234 |
| Dividend | ||
| Div. Yield | 3.75% | KR#493/2,436 Sec#17/234 |
| Div. Growth | 67.62% | KR#170/2,436 Sec#4/234 |
| Performance | ||
| 1Y Return | -41.78% | KR#1,912/2,436 Sec#168/234 |
| 1M Return | -2.55% | KR#1,348/2,436 Sec#120/234 |
| From 52W High | -67.67% | KR#2,050/2,436 Sec#181/234 |
| 1Y MDD | -72.64% | KR#2,055/2,436 Sec#183/234 |
| Trading | ||
| Volume | 24,732 shares | KR#1,560/2,436 Sec#148/234 |
| Foreign Own. | 7.99% | KR#567/2,436 Sec#52/234 |
| Per Share | ||
| EPS | 1,878 KRW | KR#413/2,436 Sec#25/234 |
| BPS | 45,112 KRW | KR#260/2,436 Sec#19/234 |
Company Info
Established as Gwangmyeong Pharmaceutical Industries in 1965, the company transitioned into a holding company in 2016. In 2021, it physically spun off its bio business, now operating as a pure holding company. As a healthcare group with 13 affiliates, including Huons and Humedix, it boasts a diverse business portfolio spanning pharmaceutical manufacturing, fillers, arthritis treatments, and medical devices. The company generates revenue from trademark usage, management consulting, dividends, and rental income, providing management guidance through subsidiary stake acquisition and ownership. Huons Global was established in 1987 and is headquartered in Seongnam-si, Gyeonggi-do.